Home / Poster / Assessing the Bioequivalence of Tacrolimus Amorphous Formulations with Varying Degrees of Crystallinity using Mechanistic Dissolution Models in a Population Physiologically-based Pharmacokinetic (PBPK) Modelling Framework

ポスター

Assessing the Bioequivalence of Tacrolimus Amorphous Formulations with Varying Degrees of Crystallinity using Mechanistic Dissolution Models in a Population Physiologically-based Pharmacokinetic (PBPK) Modelling Framework

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

ブログ

Powered by Translations.com GlobalLink Web Software

Assessing the Bioequivalence of Tacrolimus Amorphous Formulations with Varying Degrees of Crystallinity using Mechanistic Dissolution Models in a Population Physiologically-based Pharmacokinetic (PBPK) Modelling Framework

Assessing the Bioequivalence of Tacrolimus Amorphous Formulations with Varying Degrees of Crystallinity using Mechanistic Dissolution Models in a Population Physiologically-based Pharmacokinetic (PBPK) Modelling Framework

The Medicine Maker: The Biosimulation Generation

モデルを活かした医薬品開発 (MIDD) が医薬品開発の危機的状況をどのように救ったか

How is the pharmaceutical industry addressing global health inequities?

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

メルマガ登録

クイックアクセス

ソリューション

お問合せ